7.5mg Tirzepatide: Moving Into the Middle of the Schedule

Step 1: How you arrive at 7.5mg, and why the pace matters

The Mounjaro titration isn't arbitrary. Treatment opens at 2.5mg, a dose whose job is to let your body adjust to tirzepatide's effects on gastric emptying and gut-hormone signalling before any meaningful appetite suppression kicks in. After four weeks, if 5mg is tolerable, that becomes the next step, and four weeks later (assuming your prescriber is satisfied with how things are going) 7.5mg follows.

That structure exists for a reason. The most common side effects of tirzepatide are gastrointestinal: nausea, loose stools, indigestion, sometimes vomiting. Slower titration gives those effects the best chance of settling before the next increase. By the time you reach 7.5mg, many people find the early-treatment queasiness has eased considerably, and appetite suppression has become a more consistent, manageable presence rather than an occasional jolt.

If side effects at 5mg were still troublesome, your prescriber may hold that dose for longer, that's entirely within the licensed approach. The tirzepatide dosing schedule is a framework, not a countdown. Reaching 7.5mg on week eight is common, but it is not compulsory.

Worth saying plainly: if you feel anxious about increasing, that's a normal reaction. A lot of people feel the same. Raising a concern with your prescriber before the change is exactly the right thing to do.

Step 2: What 7.5mg does differently (the mechanism and the real-world experience

Tirzepatide is a dual agonist, binding to both GIP and GLP-1 receptors) the Mounjaro overview covers how those two pathways interact in depth. At higher doses, the combined effect on appetite and gastric emptying becomes more pronounced. You may find that the sense of fullness after a small portion is stronger, or that the mental preoccupation with food that many people describe as a constant background noise quietens further.

Clinical trial data helps set realistic expectations here. The SURMOUNT-1 trial, published in the New England Journal of Medicine, tracked adults receiving tirzepatide across 72 weeks. Participants who reached and stayed at the higher doses achieved average reductions of around 20–21% of body weight. Those figures come from continuing treatment to 15mg, and if you want to understand what reaching tirzepatide 7.5 mg involves in more detail, that page walks through what to expect at this specific step. Results at any individual dose step weren't the primary measure, and your own trajectory will depend on your starting weight, how your body responds, and what lifestyle changes accompany treatment.

The NICE appraisal of tirzepatide (TA1026) recommends continuing at the highest tolerated dose and reviewing progress at six months. If weight loss is less than 5% by that point, continuing treatment may not be the right path, a prescriber discussion, not a self-decision, is the appropriate next step.

Step 3: Side effects to watch for when your dose increases

Moving up to 7.5mg can bring a temporary return of symptoms that had settled, a brief recurrence of nausea or loose stools in the days after the first injection at the new strength is common and usually brief. The pattern tends to mirror what happened at earlier steps: a few days of adjustment, then improvement.

The NHS guidance on tirzepatide's side effects lists the most common ones: nausea, diarrhoea, vomiting, constipation, indigestion and reflux, burping, fatigue, headache, and injection-site reactions. These are worth knowing, not to alarm, but so that a brief recurrence doesn't feel unexpected or alarming.

A small number of people experience more significant reactions. Severe, persistent stomach pain that seems to radiate to the back (with or without vomiting) needs prompt medical attention, as this can be a sign of pancreatitis, a known but uncommon risk with this class of medicines. That symptom at any dose warrants a call to your GP or, out of hours, NHS 111. Suspected side effects can also be reported through the MHRA Yellow Card scheme.

Injection-site rotation remains important at every strength. Abdomen, thigh, and upper arm are all licensed sites, your Patient Information Leaflet covers the detail on technique and storage.

Step 4: What comes after 7.5mg, and whether you'll need to go higher

The licensed schedule continues to 10mg, 12.5mg, and 15mg, each in four-weekly steps, titrated by your prescriber. Not everyone reaches 15mg, some people find 7.5mg or 10mg is where their side-effect tolerance and weight-loss response reach a good balance, and there is no clinical requirement to push higher if you're progressing well and tolerating the current dose.

That decision happens through clinical review. At nume, every repeat order goes back to a GPhC-registered prescriber, a real clinician reads your update before any continuation or dose change is processed. If you're considering what the right next step looks like for your situation, the free consultation is the place to start that conversation.

For anyone currently on a lower dose and wondering what to expect, our page on tirzepatide 5 mg covers that step in the same detail, including how side effects and appetite changes tend to develop at that stage. And for those earlier in the process who want to understand how treatment begins, the 1 mg tirzepatide page explains the starting approach before titration gets underway. If you'd like a fuller picture of the programme as a whole before committing, our weight-loss treatment overview sets out the options clearly.